Hopital Saint Antoine
- Address
- 184 Rue du Faubourg Saint-Antoine, 75012 Paris, France
Bacterial Infections and Mycoses
At Hopital Saint Antoine, researchers are evaluating interventions aimed at reducing 90‑day all‑cause mortality in patients with Staphylococcus aureus bacteremia. The study uses an adaptive platform to compare treatment strategies and improve survival outcomes.
- Staphylococcus aureus bacteremia
- Antibiotic stewardship
- Adaptive trial design
- Mortality endpoints
The project involves eight investigators and contributes to Europe’s effort to combat severe bacterial infections.
Digestive System Diseases
Clinical work at the site focuses on patients with dMMR or MSI metastatic colorectal cancer, testing two combination regimens of nivolumab and ipilimumab. The goal is to assess safety and progression‑free survival over the first 24 weeks.
- MSI colorectal cancer
- Checkpoint inhibitor combinations
- Safety profiling
- Progression‑free survival
This research aligns with the broader European oncology network and is driven by a team of eight investigators.
Hemic and Lymphatic Diseases
The centre is conducting an adaptive trial to identify molecules that, when added to tyrosine kinase inhibitors for chronic phase chronic myelogenous leukaemia, can increase deep molecular response rates by 25 %. Participants are already in complete cytogenetic remission.
- Chronic phase CML
- Molecular response enhancement
- Combination and sequential therapy
- Drop‑loser adaptive design
Eight investigators collaborate to accelerate therapeutic options for patients with blood‑cell malignancies.
Immune System Diseases
An extension study evaluates the long‑term safety of on‑demand deucrictibant for acute attacks of hereditary angioedema, including laryngeal episodes without breathing difficulty. Participants receive oral PHA‑022121 during attacks.
- Hereditary angioedema attacks
- Laryngeal involvement
- Safety monitoring
- Oral therapeutic agent
The trial is part of a broader effort to improve quality of life for patients with rare immune‑mediated disorders.
Neoplasms
Researchers are testing elranatamab monotherapy in individuals with multiple myeloma who are refractory to proteasome inhibitors, immunomodulatory drugs and anti‑CD38 antibodies. The study measures efficacy in heavily pre‑treated patients.
- Refractory multiple myeloma
- Bispecific antibody therapy
- Efficacy endpoints
- Prior treatment exposure
This work adds to the site’s oncology portfolio and is overseen by a multidisciplinary team of eight investigators.
Respiratory Tract Diseases
A randomized trial investigates a personalized diagnostic strategy using MULTIplex PCR, procalcitonin and sputum analysis to shorten antibiotic courses during severe COPD exacerbations in the ICU. The aim is to achieve antibiotic sparing without compromising patient outcomes.
- Severe COPD exacerbation
- Biomarker‑guided therapy
- Antibiotic reduction
- ICU ventilation support
The study showcases the site’s commitment to improving respiratory care through precision medicine.
Immune System Processes
Across its portfolio, Hopital Saint Antoine emphasizes modulation of immune system processes to enhance outcomes in infection, cancer and allergy trials. The integrated approach connects cytokine inhibition, checkpoint blockade and personalized diagnostics.
- Cytokine inhibition
- Checkpoint blockade
- Personalized immune profiling
- Translational immunology
Eight investigators drive this cross‑disciplinary research, positioning the centre as a hub for immune‑focused clinical innovation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Saint Antoine
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Clindamycin Hydrochloride and Drug Combination on 90-Day Mortality in Patients with Staphylococcus aureus Bacteremia | Universitair Medisch Centrum Utrecht | Phase III | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide | 1 | Unknown | 2022-10-10 | 2022-10-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.